Sort   by:  
 Page size 
ProteomicsThe histone modifier KANSL2 is an actionable biomarker for response to epigenetic modifiers in multiple myeloma
Epigenetic aberrations are key drivers of multiple myeloma (MM), yet targeted therapies exploiting epigenetic alterations have not been established. By integrating clinical and molecular MM patient data sets with an unbiased genetic in vivoscreen, we identified KAT8 regulatory NSL complex subunit 2 ...
ORGANISM(S): Homo sapiens (Human) 
2026-02-22 | PXD066205 | Pride
Histone acetylation Hdac inhibitors Kansl2 Bet inhibitors Biomarker Multiple myeloma 
GenomicsThe histone modifier KANSL2 is an actionable biomarker in multiple myeloma
The histone modifier KANSL2 is an actionable biomarker in multiple myeloma
PRJNA1288416 | ENA
ProteomicsKansl2 dependent acetylome study in primary Kansl2 (fl/fl) murine embryonic fibroblasts
As one of the most important post-translational protein modifications, lysine acetylation is catalyzed by lysine acetyltransferases (KATs), which catalyze the covalent attachment of an acetyl group to the N epsilon–residue of lysine. The histone acetyltransferase MOF, which represents the main histo...
ORGANISM(S): Mus musculus (Mouse) 
2023-01-05 | PXD038521 | Pride
Kat8 regulatory nsl complex subunit 2  mef (murine embryonic fibroblast)  primary inducible kansl2 knock-out  cre-ert2  anti acetyl-lysine antibody  ptm enrichment 
UnknownKANSL2 and MBNL3 are regulators of pancreatic ductal adenocarcinoma invasion.
Not available
S-EPMC6992758 | biostudies-literature
UnknownThe NSL Chromatin-Modifying Complex Subunit KANSL2 Regulates Cancer Stem-like Properties in Glioblastoma That Contribute to Tumorigenesis.
Not available
S-EPMC5026635 | biostudies-literature
GenomicsNucleoli-localized KANSL2 as an epigenetic regulator of ribosome biogenesis in glioblastoma cells.
Nucleoli-localized KANSL2 as an epigenetic regulator of ribosome biogenesis in glioblastoma cells.
PRJNA1233428 | ENA
TranscriptomicsThe histone modifier KANSL2 is an actionable biomarker in multiple myeloma
Epigenetic aberrations are key drivers of multiple myeloma (MM), yet targeted therapies exploiting epigenetic alterations have not been established. By integrating clinical and molecular MM patient data sets with an unbiased genetic in vivo screen, we identified KAT8 regulatory NSL complex subunit 2...
ORGANISM(S): Homo sapiens 
2026-06-10 | GSE302047 | GEO
TranscriptomicsNucleoli-localized KANSL2 as an epigenetic regulator of ribosome biogenesis in glioblastoma cells.
KANSL2 is a subunit of the non-specific lethal (NSL) chromatin-modifying complex involved in epigenetic reprogramming and plays a critical role in tumorigenesis of glioblastoma (GBM), by enriching the GBM stem-like cell population. Analysis of KANSL2 expression in TCGA-GBM tumor samples and GTEx nor...
ORGANISM(S): Homo sapiens 
2026-01-26 | GSE291427 | GEO
TranscriptomicsThe NSL complex subunit KANSL2 regulates cell stemness and tumorigenesis in glioblastoma
The NSL (nonspecific lethal) complex proteins involved in acetyltransferase activity on histones play important role during the epigenetic and transcription regulation. The KANSL2/NSL2 is an integral component of NSL and expressed in embryonic cells. We engaged to characterize KANSL2 ( protein compo...
ORGANISM(S): Homo sapiens 
2017-02-05 | E-MTAB-4455 | biostudies-arrayexpress
GenomicsRegulation of the NSL complex by TAF4A is critical for genome stability and quiescence of skeletal muscle stem cells [CnR of KANSL2 in WT MuSCs]
Acetylation of lamin A/C by the NSL complex, containing MOF and KANSL2, is instrumental for maintaining nuclear architecture and genome stability, but the mechanisms controlling expression of NSL complex components in different cell types are poorly characterized. Here, we describe that TAF4A, prima...
ORGANISM(S): Mus musculus 
2025-09-02 | GSE277868 | GEO
Sort   by:  
 Page size